ISAL 2019 | Targeting BCL-2 in older AML: novel venetoclax combinations

Andrew Wei

Treatment options for older patients with acute myeloid leukemia (AML) are growing increasingly important. Here, Andrew Wei, MBBS, PhD, of Alfred Hospital and Monash University, Melbourne, Australia, speaks with us about the latest data on venetoclax in this setting at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany. Dr Wei highlights the importance of specific mutations in determining response and how best to give venetoclax; for example, patients with TP53 mutations can be hard to treat but the novel agent APR-246 is being investigated in combination with venetoclax for this group.

Share this video